BOSTON, February 18, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated ... Executive Vice President and Chief Financial Officer, and Dr. Altshuler will participate in a fireside chat ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... Charles Wagner, Executive Vice President and Chief Financial Officer, and Dr. Altshuler will participate in a fireside chat at ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 in a research note issued to investors on Thursday,Benzinga reports.

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its payroll year over year. The Boston-based drugmaker employed 6,100 ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

BOSTON - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported fourth-quarter revenue that exceeded analyst estimates, driving its stock up 0.8% in after-hours trading Monday. The ...